Kane Biotech (TSXV:KNE) Expands revyve Reach Across North American Wound Care Markets
Highlights
- Kane Biotech targets chronic wounds by disrupting biofilms, killing bacteria and supporting the healing environment.
- The company holds three US FDA 510(k)-cleared revyve products, with its wound gel and spray also approved in Canada.
- Kane expanded distribution, federal procurement access and sales coverage across North America during early 2026.
Chronic wounds remain a significant healthcare challenge, often persisting because bacterial biofilms protect microorganisms from antibiotics, disinfectants and the body’s immune response. Kane Biotech Inc.
(TSXV:KNE)
0.03
CAD
0.000
0.000%
Last Updated at: 2026-08-05T17:42:00Z
has built its human wound care strategy around addressing this treatment gap through its revyve portfolio, which combines regulatory-cleared products with an expanding commercial network across multiple care settings in North America.
Large Chronic Wound Market Supports Commercial Opportunity
The scale of chronic wound care provides the foundation for Kanes strategy. In the United States, around 10.5mn Medicare beneficiaries suffer from chronic wounds, while approximately 130,000 amputations occur annually among diabetic patientsequivalent to one every four minutes.
Burn care adds another layer to the burden, with around 700,000 insurance claims and 29,000 hospital admissions each year. Average treatment costs can exceed USD 100,000 per burn.
Canada faces similar pressure. Diabetic amputations carry an average hospitalisation cost of CAD 47,000, while annual hospital costs linked to lower-limb diabetes complications reach around CAD 750mn. Total direct spending on wound care is estimated at more than CAD 12bn annually.
Biofilms Define the Treatment Gap
Kanes business centres on the role of biofilms in non-healing wounds. Biofilms are present in 70% of burn wounds and 80% of chronic wounds. Bacteria within these protective structures can be 1,000 times more resistant to antibiotics than regular bacteria.
Existing options leave gaps. Surgical debridement can be painful and requires clinical intervention, while biofilms may reform within 24 hours. Conventional hydrogels do not actively disrupt biofilms and may require daily changes. Advanced dressings can cost more than USD 1,000, while antibiotics may penetrate biofilms poorly and contribute to resistance.
Three Functions Shape the revyve Platform
The revyve platform combines biofilm disruption, antimicrobial activity and healing support within a single treatment approach. Its patented coactiv+ technology breaks down the biofilm matrix, exposing bacteria and reducing elevated protease activity.
The antimicrobial component provides bacterial killing for up to seven days without antibiotics, including activity against multi-species and resistant strains. A thermo-reversible gel supports autolytic debridement and maintains a moist wound environment.
Kanes portfolio currently includes antimicrobial wound gel, antimicrobial wound spray and antimicrobial skin and wound cleanser. All three are US FDA 510(k) cleared, while the gel and spray are also approved by Health Canada.
The gel targets diabetic foot ulcers, leg ulcers, pressure ulcers and surgical incisions, while the non-aerosol spray is designed for burns, trauma and painful wounds.
Distribution Expansion Supports Commercial Growth
Kane estimates a US market opportunity of USD 423mnUSD 493mn, including approximately USD 350mn across chronic wounds and USD 80mnUSD 150mn across inpatient burn and wound care.
To access these markets, the company signed multiple non-exclusive distribution and sales agent agreements across targeted US regions and channels. Its relationship with Marathon Medical Corporation provides access to federal procurement systems, including Veterans Affairs, the Department of Defense and Indian Health Services.
Kane also shifted its Canadian agreement with Best Buy Medical Canada to a non-exclusive model, added business development leadership in both countries and expanded its contract-based US sales team.
Kane ended March 2026 with CAD 395,058 in cash before completing an oversubscribed CAD 1.16mn private placement in May. As shipments under new partnerships continue to ramp during the second quarter, the companys next phase centres on converting regulatory clearance, clinical validation and expanding distribution network into broader adoption of the revyve portfolio and growing commercial revenue.
KNE shares last traded at CAD 0.025 on August 05, 2026.
